Skip to main content

SWTX

Stock
Health Care
Biotechnology

Performance overview

SWTX Price
Price Chart

Forward-looking statistics

Beta
1.37
Risk
73.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Company info

SectorHealth Care
IndustryBiotechnology
Employees283
Market cap$3.0B

Fundamentals

Enterprise value$3.3B
Revenue$219.7M
Revenue per employee—
Profit margin-115.60%
Debt to equity1.77

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.41
Dividend per share—
Revenue per share$2.95
Avg trading volume (30 day)$202M
Avg trading volume (10 day)$189M
Put-call ratio—

Macro factor sensitivity

Growth-2.6
Credit+5.9
Liquidity+1.2
Inflation-4.0
Commodities-1.8
Interest Rates-3.0

Valuation

Dividend yield0.00%
PEG Ratio-21.96
Price to sales16.12
P/E Ratio-21.96
Enterprise Value to Revenue14.84
Price to book8.44

Upcoming events

Next earnings dayMay 10, 2025
Next dividend day—
Ex. dividend day—

News

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.

Zacks Investment Research (May 26, 2025)
Top 3 Health Care Stocks You May Want To Dump In February

As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga (February 20, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free